A Study of [14C]IBI351 in Healthy Subjects

Innovent Biologics (Suzhou) Co. Ltd.6 enrolled

Overview

This study is to evaluate the mass balance of single oral dose of \[14C\] IBI351 in healthy subjects. Six to eight healthy male subjects were planned to be enrolled. After passing the screening, subjects were admitted to hospital and received training on medication, urine and feces collection and other procedures to ensure that they could perform relevant operations according to the protocol and SOP requirements. On the evening before medication, the patient had standard meals, and fasted uniformly overnight. On D1, the suspension containing recommended dose of \[14C\] IBI351 was administered in the morning on an empty stomach. Subjects have standardized meal during the trial and blood, urine, and feces samples were collected and safety laboratory tests were performed as scheduled.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Healthy Subjects

Interventions

Eligibility

Sex: MALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria： 1. Voluntarily sign the informed consent form before the trial, and fully understand the content, process and possible adverse reactions of the trial. 2. Healthy male subjects aged 18 to 45 years (including both ends) at the time of signing informed consent. 3. Body weight is not less than 50 kg, and body mass index (BMI) is in the range of 19 \~ 26 kg/m2 (including both ends). 4. Vital signs, physical examination, laboratory tests (including blood routine, urine routine, blood biochemistry, coagulation, etc.), chest radiography, 12-lead ECG and other results were unremarkable; or abnormal examination results but judged by the investigator as clinically insignificant. Exclusion Criteria 1. allergic constitution; known hypersensitivity to any component of the test drug or its preparation. 2. have special requirements for diet and cannot abide by the unified diet; or lactose intolerance. 3. history of dysphagia or any gastrointestinal disease that affects drug absorption. 4. blood donation or massive blood loss (\> 200 mL) within 3 months before screening, or blood transfusion within 1 month. 5. Have taken an investigational product or participated in any clinical trial within 3 months before taking the study drug.